MediciNova, Inc. Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2018; filed February 13, 2019. The filing also presents unaudited fourth-quarter data. MediciNova is a clinical-stage biopharmaceutical company developing small-molecule therapeutics and has no approved products or product sales.
Business Context and Pipeline
- Primary programs are MN-166 (ibudilast) for progressive multiple sclerosis, ALS, substance dependence, glioblastoma and other neurological indications, and MN-001 (tipelukast) for NASH and idiopathic pulmonary fibrosis.
- Additional programs include MN-221 (bedoradrine) for acute asthma exacerbations and MN-029 (denibulin) for solid tumors.
- The company relies on third parties for clinical trials, manufacturing and, if products are approved, expects to rely on strategic partners for commercialization.
- As of the filing date, the company had nine full-time employees and no laboratory, research or manufacturing facilities.
Financial and Liquidity Metrics
| Metric | 2018 | 2017 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research, development and patent expense | $5.6 million | $4.2 million | Up $1.4 million |
| General and administrative expense | $10.0 million | $8.8 million | Up $1.2 million |
| Total operating expenses | $15.6 million | $13.0 million | Up $2.6 million |
| Operating loss | $15.6 million | $13.0 million | Worsened by $2.6 million |
| Interest income | $0.9 million | $0.1 million | Up $0.8 million |
| Net loss | $14.7 million | $11.2 million | Worsened by $3.5 million |
| Basic and diluted loss per share | $0.36 loss | $0.32 loss | Worsened by $0.04 |
| Cash used in operating activities | $9.1 million | $6.9 million | Use increased by $2.2 million |
| Cash and cash equivalents at year-end | $62.3 million | $28.0 million | Up $34.3 million |
| Working capital | $60.6 million | $25.4 million | Up $35.1 million |
The company reported total assets of $77.2 million, total liabilities of $4.1 million and stockholders’ equity of $73.1 million at December 31, 2018. It had no outstanding warrants and disclosed no material debt. Accumulated deficit was $356.1 million.
Fourth-quarter 2018 operating expenses were $0.5 million and net loss was $0.2 million, compared with fourth-quarter 2017 operating expenses of $3.4 million and net loss of $1.6 million. The filing does not identify the specific reason for the unusually low fourth-quarter 2018 expense and loss levels beyond the annual discussion of expense fluctuations.
Material Changes Versus the Prior Comparable Period
- Research and development expense increased primarily because of greater clinical trial activity for MN-166 and higher performance-based stock compensation.
- General and administrative expense increased primarily because of higher performance-based stock compensation.
- Interest income increased materially as a result of the substantially larger cash balance.
- Cash increased primarily from financing activities: approximately $37.4 million of net proceeds from a February 2018 public offering, $1.5 million of net ATM proceeds and $2.4 million of gross warrant-exercise proceeds.
- Investing activities provided $0.6 million from dissolution and liquidation of the Zhejiang Sunmy joint venture.
- Shares outstanding increased from approximately 36.5 million at year-end 2017 to 42.1 million at year-end 2018, reflecting equity financing and exercises.
- Share-based compensation rose to $6.3 million from $4.5 million and represented a significant portion of operating expenses.
Clinical, Regulatory and Management Outlook
- SPRINT-MS Phase 2b results for MN-166 showed a statistically significant 48% reduction in the rate of whole-brain atrophy versus placebo and a 26% reduction in the risk of confirmed disability progression; the results were published in the New England Journal of Medicine in August 2018.
- MN-166 received FDA Fast Track designations for progressive MS, ALS and methamphetamine dependence, and orphan-drug designations for ALS and glioblastoma-related development.
- The methamphetamine dependence Phase 2 trial did not meet its primary abstinence endpoint in March 2018.
- The MN-001 NASH/NAFLD trial was terminated early after an interim analysis showed a statistically significant reduction in mean serum triglycerides. The filing notes that the analysis included 15 subjects who completed eight weeks of treatment.
- The MN-001 Phase 2 IPF trial was enrolling patients. MN-166 trials in ALS, addiction, chemotherapy-induced peripheral neuropathy and glioblastoma-related development were ongoing or planned.
- Management expected research and development expenses to increase in 2019 and stated that available working capital was sufficient to fund operations through the end of 2020, based on assumptions regarding development spending.
- Management intends to seek strategic alliances and potential out-licensing arrangements after proof-of-concept milestones. Additional capital may be required depending on development decisions.
Key Risks, Contingencies and Unusual Items
- The company has no approved products, no product revenue and expects continuing losses for the foreseeable future. It may need additional financing, partnerships or asset sales to continue development.
- Future financing could dilute shareholders or impose restrictive debt terms. The company maintains an ATM facility with aggregate capacity of up to $30.0 million, subject to available capacity and market conditions.
- All product candidates remain subject to clinical, regulatory, manufacturing, safety, efficacy and market-acceptance risks. Fast Track and orphan-drug designations do not guarantee approval.
- MN-166 lacks composition-of-matter patent protection, and the U.S. method-of-use patent for MS expired in August 2018. The company relies primarily on method-of-use, formulation, process and other patent rights.
- Potential future milestone payments under license agreements totaled approximately $43.5 million at year-end 2018, including $10.0 million for MN-166 and MN-001 and $33.5 million for other products; timing is uncertain and royalties may be payable on future sales.
- Contractual obligations included approximately $2.8 million of operating leases and estimated research and development services, principally due within one to three years.
- No material legal proceedings, off-balance-sheet arrangements or goodwill impairment were reported. The independent auditor issued unqualified opinions on the financial statements and internal control over financial reporting.
- Deferred revenue of approximately $1.7 million remains from the Kissei collaboration; the timing of the related second study and revenue recognition is undetermined.
Investor Verification Checklist
- Verify the company’s cash runway against the pace and scope of planned MN-166 and MN-001 clinical development.
- Review subsequent clinical, regulatory and partnering updates, particularly for progressive MS, ALS, IPF and glioblastoma.
- Assess the implications of the expired MS patent and the broader strength and duration of method-of-use patent protection.
- Track potential milestone obligations, royalty terms and any changes to licensed rights.
- Monitor equity issuance, ATM utilization, option dilution and future capital requirements.
- Reconcile fourth-quarter 2018’s unusually low operating expenses and net loss with the underlying quarterly financial statements and subsequent filings.